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Abstract 
The anti-malarial activity of the arenearylpyrimidylmethane (AAPM) class of compounds emerged 
from database searching of a pharmacophore. A new 2 step synthesis of the AAPM scaffold is 
reported and subsequent substitution yielded a short synthesis of the lead anti-malarial compound. 
The presence of atropisomerism in this class of compounds is also reported for the first time. 
 
Introduction 
Malaria is a serious endemic disease that has resisted all efforts of eradication, and control for over 
a century. It is a major threat to public health in more than 100 countries[1] affecting more than 500 
million people per year, with an associated 2.7 million deaths.[2] The economic toll of malaria is 
tremendous[2] and with the increasing globalization of commerce, the number of travellers to areas 
of high risk is increasing each year.[3] Thus, the need for a continual supply of new anti-malarial 
therapeutics is still as relevant as ever. Malaria is caused by the protozoan parasite,[4] with P. 
falciparum being responsible for most malaria related deaths. 
 
We recently reported a serendipitous result where a series of new lead compounds as anti-malarial 
agents were unearthed from a study probing potential anti-HIV agents.[5] In summary, a series of 
pharmacophores were generated using different compound classes of non-nucleoside reverse 
transcriptase inhibitors of HIV-1 and were used as filters in database searching. Although none of 
the samples obtained showed HIV-1 reverse transcriptase inhibition, they were also subjected to 
anti-malarial testing in a random screening study. Of the 15 compounds tested, 9 showed significant 
activity, indicating that our pharmacophores and screening strategy are excellent for revealing new 
anti-malarial leads. Most of these structures were previously reported by us,[5] however, we publish 
here the two most active anti-malarial compounds that emerged from this study (1 and 2, Figure 1). 
Of particular interest was the arenearylpyrimidylmethanes (AAPM) 1 – not only was this our most 
active anti-malarial lead, it also has a scaffold that is comparable to the known arenediarylmethanes 
(ADAM)(e.g. 3,[6] Figure 1), which have been extensively reported as anti-HIV agents targeting the 
reverse transcriptase enzyme.[6] Given the significant activity, the synthesis and retesting of 1 as a 































Figure 1: The two most active anti-malarial leads that serendipitously emerged from an anti-HIV 
drug discovery program.[5] The anti-malarial activity was measured using the WHO approved 
Desjardins method[7] against multi-drug resistant P. falciparum and is reported as the IC50 in μmol. 
The arenediarylmethane (ADAM) 3 is an example of a known anti-HIV reverse transcriptase 
inhibitor.[6] 
 
Results and Discussion 
The development of a convergent synthetic strategy to the AAPM structural scaffold is important 
for the development of structure-activity relationships (SAR) via the synthesis and testing of 
analogues. The key intermediate is the AAPM 6 – subsequent chemistry to produce the final target 
is routine. However, the one published synthesis of 6 is a 5 step linear sequence with an overall 
yield of 24% and contains little convergence.[8,9] We have developed a 2 step sequence for the 
synthesis of 6 starting from analogous materials to the published synthesis (Scheme 1) with an 
overall yield of 34% – this more than halving of the synthetic steps required to produce the key 
intermediate allows for quick access to the AAPM structural scaffold. 
 
The nucleophilic addition of 5-lithiated-4,6-dichloropyrimidine 4 to p-chloroisobutyrophenone 
yielded the alcohol 5 in modest yield (43-45%) which upon dehydration gave 6 in 74-78% yield. 
The steric hindrance associated with the initial nucleophilic addition is significant but is necessary 
in order to allow for the required substitutions for subsequent derivatisation. The conversion of 6 to 
the final lead AAPM compound 1 was achieved using standard conditions[8] of monoamination at 
140 °C using aqueous ammonia yielding 6, followed by amination at 200 °C with 1-amino-3-
diethylamino-2-propanol. In our hands, the reverse sequence of amination to initially produce 8 (see 
Figure 2) failed in the subsequent addition of ammonia, presumably due to the ever increasing steric 
interactions associated with the bulky adjacent substituents. 
 
The straightforward synthesis of 1 is complete in 4 steps (c.f. 7 steps previously reported[8,9]) with 
the AAPM scaffold being produced in 2 steps, and is convergent and quick, utilising cheap readily 















a) LDA, THF, -78 oC, 1h






























5a X = H,  45%
5b X = Cl, 43%
6a X = H,  74%
6b X = Cl, 78%
7a X = H,  74%
7b X = Cl, 75%1 X = Cl, 40%
X = Cl, H
8a X = H,  72%




Scheme 1: The short, convergent synthesis of the arenearylpyrimidylmethanes (AAPM) skeleton 6, 
and the subsequent derivatisation yielding the total synthesis of the lead anti-malarial compound 1. 
 
The AAPM 1 has been reported as being negative in anti-malarial testing.[9] However, a second 
sample from the NCI and a sample prepared from our synthetic route were retested and confirmed 
the anti-malarial activity of 1. 
 
Analysis of the 13C NMR and 1H NMR spectra of 1, 8a, and 8b (Figure 2) revealed a doubling of 
peaks of approximately equal intensity, indicating the presence of atropisomers. Atropisomerism is 
a phenomenon which results from slow rotation about a single bond[10] and can be observed here 
due to the presence of diastereoisomers arising from the atropisomeric bond and the presence of the 
racemic alcohol. Further confirmation of the likelihood of atropisomers is the absence of such 
doubling of peaks in the nmr spectra in systems where atropisomerism would not be expected, e.g. 
when the substituents adjacent to the relevant bond are identical (e.g. 6) or if the relevant 
substituents are not sufficiently large to restrict the bond rotation (e.g. 7). The presence of 







X = Cl, R = Cl, 8b 
X = H,  R = Cl, 8a



























Figure 2: Atropisomerism due to a barrier of bond rotation in compounds 1, 8a and 8b. An asterisk 
indicates restricted rotation around the single bond. 
 
Conclusions 
A short 2 step synthesis to the arenearylpyrimidylmethanes (AAPM) heterocyclic scaffold has been 
developed and subsequent derivatisation to produce the lead anti-malarial compound 1 was 
successfully completed. The biological activity of 1 was confirmed by retesting of the synthesised 
sample. The presence of atropisomerism was observed in suitably substituted examples.  
 
Supporting Information 
The synthetic procedures and spectroscopic data for compounds 1, 5a, 5b, 6a, 6b, 7a, 7b, 8a, and 
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Anti-malarial testing 
The parasite P. falciparum (K1, multidrug-resistant strain) was cultured continuously according to 
the method of Trager and Jensen.[11] Quantitative assessment of anti-plasmodial activity in vitro was 
undertaken by means of the microculture radioisotope technique based upon the method described 
by Desjardins et al.[7] Inhibition concentration (IC50) represents the concentration which causes 50% 
reduction in parasite growth as indicated by the uptake of [3H]-hypoxanthine by P. falciparum. 
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